Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of SP-02L (Darinaparsin for Injection) in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea

NCT01689220 is registered in ClinicalTrials.gov with Solasia Pharma K.K. as lead sponsor.

NCT NCT01689220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01689220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of SP-02L (Darinaparsin for Injection) in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea
Lead sponsor
Solasia Pharma K.K.
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2012
Completion date
September 30, 2014
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral t-cell lymphoma